Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Ovestin for Vulvovaginal Atrophy in Postmenopausal Women
2017-004864-37Phase 3Terminated
- Sponsor
- Aspen Global Incorporated
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in vaginal atrophy comparing Ovestin with Placebo (2 arms). Primary endpoint: Change in most bothersome symptom at Week 12. Started Mar 2018; status: terminated.
02
Drugs
estriol
03
Conditions
vaginal atrophy
Beyond the preview
Go deeper on 2017-004864-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004864-37.